Hennigsdorf, Germany Clinical Trials

A listing of Hennigsdorf, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 3 clinical trials
Pazopanib vs. Pazopanib Plus Gemcitabine

This study is a prospective, randomized, open-label, multicenter phase II trial in order to determine progression-free survival of patients with refractory or relapsed metastatic uterine leiomyosarcomas or other metastatic uterine tumours.

Charit Campus Virchow-Klinikum Universit tsmedizin Berlin
 (8.8 away) Contact site
  • 2 views
  • 28 Jan, 2021
  • +15 other locations
Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb

The purpose of this study is to assess safety and efficacy of BAY1817080 compared to elagolix and placebo in women with symptomatic endometriosis. Study details include: Study duration: 155 up to 285 days Treatment duration: 84 days Visit frequency: approximately once a month

laparotomy
analgesic
elagolix
laparoscopy
endometriosis
Charit - Campus Virchow-Klinikum (CVK)
 (8.8 away) Contact site
  • 0 views
  • 03 Jun, 2021
  • +201 other locations
A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)

Keyriched-1 is a multicenter, interventional, prospective, single arm, open label, neoadjuvant phase II trial evaluating the pathological complete response (pCR) rate induced by pembrolizumab in combination with the dual anti-HER2 blockade consisting of trastuzumab biosimilar ABP 980 and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype tested …

pertuzumab
erbb2
mammogram
magnetic resonance imaging of breast
progesterone receptor
Ev. Waldkrankenhaus Spandau
 (4.9 away) Contact site
  • 89 views
  • 26 Jan, 2021
  • +14 other locations